NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

I WAS WRONG: Both the CTBEAG and the CHM reviewed the same treatment (DCVax-L) BUT:

"The Clinical Trials, Biologicals and Vaccines Expert Advisory Group (CTBVEAG) review on November 24, 2025, did not issue a negative assessment regarding the clinical safety or efficacy of DCVax-L. While it is standard for public regulatory minutes to trigger speculative online investor discussions about safety questions, the core points raised in late 2025 regarding Northwest Biotherapeutics' (NWBO) Marketing Authorization Application (MAA) focused primarily on manufacturing validation, chemistry, manufacturing, and controls (CMC), and data handling rather than any newfound toxicity or clinical danger.Safety Profile. Your intuition regarding the compassionate use program is correct. Having been utilized for years under the UK's Named Patient / Compassionate Use program and evaluated in a major Phase III trial, DCVax-L has established a well-documented safety profile. The clinical data consistently demonstrates that the treatment is highly tolerable, with very few serious adverse events reported. The Regulatory Flow and Timeline: The relation between the two dates you highlighted follows a standard, sequential regulatory process rather than a conflicting one: November 24, 2025 (CTBVEAG Meeting): As an Expert Advisory Group reporting directly to the Commission on Human Medicines (CHM), the CTBVEAG's role is to evaluate specific technical, biological, and clinical trial aspects of an application. They compile their expert input and raise "points for clarification". November 27–28, 2025 (CHM Review): The CHM is the senior overarching body. The timing of these meetings is intentionally linked. The CHM relies directly on the fresh briefing papers, conclusions, and specific points raised by the CTBVEAG just days prior to shape their broader assessment of the MAA. Rather than a rejection, questions raised at this stage of an advanced therapy review typically represent a "Day 180" style list of remaining questions. These frequently concern the scaling of personal cell-therapy manufacturing—such as the validation of NWBO's Sawston facility and automated cleanroom methodologies—which the applicant must satisfy before final authorization can be granted"